American stock indices ended trading lower on Monday, but showed record monthly gains and November dynamics.
According to investors, the main drivers of recent market growth were two factors: the development of three vaccines for COVID-19, which gave hope that the economic turmoil caused by the coronavirus pandemic will subside in 2021, and the easing of political uncertainty after the US presidential election. ... The prospect of vaccines "means some light at the end of the tunnel for investors", said Royal London Asset Management expert Trevor Gritham, quoted by Dow Jones.
Meanwhile, the market may be under pressure from the risk of an increase in the number of COVID-19 diseases after Thanksgiving, analysts say. The epidemiological situation in the United States after Thanksgiving, in connection with which many Americans travel around the country, is likely to worsen even more, chief American infectious disease specialist Anthony Fauci told ABC. "We understand the importance of bringing relatives together. And this is what we have to deal with when we are likely to have an increase in the number of cases (coronavirus COVID-19) as the colder weeks of winter come and we are approaching the Christmas season.", - he said.
The Dow Jones Industrial Average by the close of trading dropped by 271.73 points (0.91%) and amounted to 29638.64 points. At the same time, according to the results of the past month, the indicator increased by 11.84%, which was the highest rise since January 1987. November of this year was the best for the index in terms of growth in percentage terms since 1928.
Standard & Poor's 500 fell by 16.72 points (0.46%) - to 3621.63 points. The indicator also posted a record monthly gain since April, up 10.75%. For the index, this was the best growth in November since 1928..
The Nasdaq Composite lost 7.11 points (0.06%) and amounted to 12198.74 points. At the end of the month, the index strengthened by 11.8% - the maximum since April. This is the most significant increase in November since 2001.
American company Moderna (NASDAQ: MRNA) Inc. on Monday published the final data of the final phase of vaccine trials and announced that it will send a request to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for permission to use the vaccine it has developed against COVID-19. The FDA vaccine committee meeting to evaluate the safety and effectiveness of the vaccine is likely to take place on December 17. According to the document, the company expects the distribution of the vaccine throughout the United States to begin "shortly after obtaining a permit for emergency use".
Moderna shares soar by 20.24% by the end of trading.
S Shares&P Global Inc. rose 3%, IHS Markit Ltd. - by 7.4%. The companies entered into a merger agreement, under which IHS is valued at $ 44 billion, including a debt of $ 4.8 billion.
Meanwhile, Nikola Corp. fell by 26.92%. American automaker General Motors Co. (SPB: NYSE: GM) (GM) will supply fuel cells to the electric truck maker, but will not receive a stake in the startup as part of a new, cut-back partnership agreement announced Monday. Nikola will also ditch plans for a Nikola Badger pickup truck, which were part of a previous deal with GM, unveiled in September, according to company press releases..
GM shares lost 2.71% in price.
The Dow Jones was under pressure from Salesforce.com (NYSE: CRM) Inc. and Chevron Corp (NYSE: CVX), which slipped 0.7% and 4.5%, respectively.
Комментарии
Отправить комментарий